CAR T-cell therapy reprograms a patient's own T-cells into a living drug that hunts and destroys cancer cells, marking the start of modern cellular immunotherapy. The hosts credit researchers including Carl June at the University of Pennsylvania and Steven Rosenberg at NIH, along with a colleague at Memorial Sloan Kettering, with developing the approach, which led to the first FDA-approved cell-based gene therapies and an expanding pipeline of treatments for cancer.
178 words · auto-generated from the episode video
2:03:03doing really really great things. Carl June at the University of Pennsylvania, Steven Rosenberg at NIH, and Michael Sateline at MSKCC. They revolutionized oncology with this CARTT cell therapy. It's a living drug that programs te- cells to hunt and destroy cancer cells. It's it's pretty incredible, right? It inaugurated the modern era of cellular imunotherapy. It's leading the leading to the first FDA approved cell-based gene therapies and creating a robust rapidly evolving pipeline for you know treating these types of malignancies. >> It's incredible the again you see these things all building on each other. We
2:03:43are getting close to the end of our list and something we mentioned earlier about splicing made me think of this 2012 >> discovery the development of crisper cast 9 genome editing. Another thing we talk about often on the podcast. >> Yes. This is the graduation of the restriction enzyme concept. Before we had the idea of restriction enzymes, which were specific enzymes that looked for specific patterns in the DNA for where to cut. Here we've got a